The transdermal drug delivery system market is expected to grow from US$ 37,230.28 million in 2022 to US$ 51,949.74 million by 2030; it is anticipated to record a CAGR of 4.3% from 2022 to 2030. Strategic initiatives by manufacturers will likely remain a key trend in the market.

Transdermal Drug Delivery System Market Analysis

The increasing prevalence of chronic diseases, growing demand for noninvasive drug delivery devices, and high demand for self-administration of drugs are the key driving factors behind the market growth. Furthermore, adopting 3D printing technology and smart patches will likely offer opportunities to the transdermal drug delivery systems market in the coming years.

Transdermal Drug Delivery System Market Overview

Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs, but conventional capsules and tablets are unable to control the ailment effectively. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the heart's stress, lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Transdermal Drug Delivery System Market: Strategic Insights

Transdermal Drug Delivery System Market

• 
  CAGR (2022 - 2030)

  4.3%
• Market Size 2022
  US$ 37,230.28 Million
• Market Size 2030
  US$ 51,949.74 Million

Market Dynamics

GROWTH DRIVERS

• Introduction of advanced transdermal drug delivery systems to boost their global uptake

FUTURE TRENDS

• Adoption of 3D printing technology and smart patches is likely to offer opportunities to the transdermal drug delivery systems market

OPPORTUNITIES

• Advantages associated with a noninvasive drug delivery facilitated by transdermal drug delivery systems to drive the market growth

Key Players

• Novartis AG
• GSK Plc
• Viatris Inc
• Boehringer Ingelheim International GmbH
• Lavipharm SA
• Hisamitsu Pharmaceutical Co Inc
• Johnson & Johnson
• Luye Pharma Group Ltd
• Purdue Pharma LP.

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Transdermal Patches
• Transdermal Gel
• Transdermal Sprays
• Others

Application

• Cardiovascular Diseases
• Central Nervous System Disorders
• Pain Management
• Hormonal Applications
• Other Applications

Distribution Channel

• Hospitals Pharmacies
• Retail Phamacies
• Online Pharmacies
• Others

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Transdermal Drug Delivery System Market Drivers and Opportunities

Continuous Technological Advancement

Traditional drug delivery techniques such as intramuscular, intravenous, and rectal drug administration are not preferred by specific patient populations, mainly due to the pain and complexities associated with them. With the improvements in medical science and definite drug delivery technologies, noninvasive drug delivery systems are now set to compete with the traditional method of injectable drug administration. The noninvasive drug delivery systems include drug delivery via oral, topical, transdermal-active (device-aided enhanced penetration), and transdermal-passive; transocular membrane, transmucosal membrane, and alveolar membrane from inhaled medication. Transdermal drug delivery is advantageous in many ways over the oral route of administration. In particular, it evades the first-pass mechanism of the liver, which can otherwise impulsively metabolize drugs.

Advancements in Smart Patches and 3D-printed Patches

A transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being conducted in this field and the increasing interest of researchers in this form of drug delivery, many transdermal patches are likely to reach the marketplace in the future. Transdermal patches are used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various medical conditions. Recently, these patches have been explored to deliver biologics in various applications. Smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly. In January 2023, a lead scientist at Swansea University developed a new smart patch to detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson's and Alzheimer's using the microneedle technology. These smart patches comprise numerous microneedles designed to penetrate the skin barrier in a minimally invasive manner, followed by monitoring the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at general practices or home. This innovative research can potentially change the landscape of early neurodegenerative disease detection.

Transdermal Drug Delivery System Market Report Segmentation Analysis

Key segments that contributed to the derivation of the transdermal drug delivery system market analysis are product and end user.

• Based on type, the transdermal drug delivery system market is segmented into event transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal patches segment held the largest market share in 2022.
• Based on application, the transdermal drug delivery system market is segmented by cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, other applications. The pain management segment held a largest market share in 2022.
• Based on the distribution channel, the transdermal drug delivery system market is segmented by hospitals pharmacies, retail phamacies, online pharmacies, others. The hospitals pharmacies segment held a largest market share in 2022.

Transdermal Drug Delivery System Market Share Analysis by Geography

The geographic scope of the transdermal drug delivery system market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

The US is the largest market for transdermal drug delivery systems in North America. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, patient monitoring, and compliance. According to a report titled "Recent advances in transdermal drug delivery systems," published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases..

Transdermal Drug Delivery System Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Transdermal Drug Delivery System Market News and Recent Developments

The Transdermal Drug Delivery System Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the transdermal drug delivery system market are listed below:

• Starton Therapeutics Inc. has filed provisional patent applications with the U.S. Patent and Trademark Office (USPTO) for unique and novel approaches to incorporate various active pharmaceutical ingredients (APIs) into transdermal drug delivery systems, where such APIs have typically been difficult to incorporate in a transdermal drug delivery system platform. (Source: Starton Therapeutics, Company Website, January 2024)
• Satio has received a $3.5 million Small Business Innovation Research (SBIR) contract from Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services. This SatioRx device is designed to be compact and inexpensive, with disposable microneedle components that allow healthcare providers to remotely deliver a precise metered dose of any liquid drug approved for transdermal delivery by the FDA. Under this contract, Satio will leverage design features from its other patch-based devices and feasibility data from its manually operated transdermal delivery devices to develop the next-generation remotely controllable device. (Source: Satio, Company Website, September 2023)

Transdermal Drug Delivery System Market Report Coverage and Deliverables

The “Transdermal Drug Delivery System Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:

• Transdermal drug delivery system market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Transdermal drug delivery system market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Transdermal drug delivery system market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the transdermal drug delivery system market
• Detailed company profiles